Skip to main content

Table 2 Multivariate Cox regression analysis of the clinicopathogical parameters for overall survival and progression free survival

From: Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer

  Overall survival   Progression free survival
  HR 95% CI P HR 95% CI P
FIGO stage (early stage vs. advanced stage) 1.127 0.357–3.562 0.838 1.744 0.576–5.288 0.325
Histologic grade (well vs. poor and moderate) 0.615 0.256–1.475 0.276 0.904 0.393–2.077 0.811
Ascites (no vs. yes) 0.850 0.381–1.897 0.692 0.667 0.337–1.323 0.247
LN metastasis (no vs. yes) 0.924 0.460–1.856 0.823 0.786 0.410–1.506 0.468
Age (≤50 vs. >50 years) 2.920 1.466–5.815 0.002 2.403 1.302–4.435 0.005
Preoperative CA125 (U/ml) (≤600 vs. >600) 0.548 0.280–1.073 0.079 0.327 0.177–0.607 0.000
DOT1L expression (low vs. high) 4.705 2.160–10.248 0.000 8.884 3.974–19.861 0.000
  1. HR hazard ratio, CI confidence interval